Bill Baruch Likes AbbVie’s Breakout as Humira Losses Get Replaced
Bill Baruch is looking at AbbVie as a healthcare name outside of the tech trade. He pointed to 7 percent earnings growth and an expected 24 percent revenue growth ahead, with Skyrizi and Rinvoq now making up for the revenue AbbVie lost as Humira came off patent. The stock is only up about 7 percent […]